Literature DB >> 11317227

Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia.

R H Segman1, U Heresco-Levy, B Finkel, T Goltser, R Shalem, M Schlafman, A Dorevitch, A Yakir, D Greenberg, A Lerner, B Lerer.   

Abstract

Tardive dyskinesia (TD) is a long-term adverse effect of antipsychotic drugs that are dopamine D2 receptor blockers.(1) Serotonin receptor antagonism has been proposed as a common mechanism contributing to the low extrapyramidal effects profile of atypical antipsychotic drugs.(2) We examined the association of three polymorphisms in the 5-HT2A receptor gene (HTR2A) with TD susceptibility--T102C(3) and his452tyr(4) in the coding region and A-1438G(5) in the promoter--in matched schizophrenia patients with (n = 59, SCZ-TD-Y) and without TD (n = 62, SCZ-TD-N) and normal control subjects (n = 96). The T102C and the A-1438G polymorphisms are in complete linkage disequilibrium but not his452tyr. There was a significant excess of 102C and -1438G alleles (62.7%) in the SCZ-TD-Y patients compared to SCZ-TD-N patients (41.1%) and controls (45.9%; chi(2) = 12.8, df = 2, P = 0.002; SCZ-TD-Y vs SCZ-TD-N, chi(2) = 11.4, df = 1, P = 0.0008, OR 2.41, 95% CI 1.43-3.99) and of 102CC and -1438GG genotypes (SCZ-TD-Y 42.4%, SCZ-TD-N, 16.1%, controls 20.8%, chi(2) = 13.3, df = 4, P = 0.01). The 102CC and the -1438GG genotypes were associated with significantly higher AIMS trunk dyskinesia scores (F = 3.9; df = 2, 116; P = 0.02) and more incapacitation (F = 5.0; df = 2, 115; P = 0.006). The his452tyr polymorphism showed no association with TD. These findings suggest that the 5-HT2A receptor gene is significantly associated with susceptibility to TD in patients with chronic schizophrenia. Previously reported association of the T102C and A-1438G polymorphisms with schizophrenia(6) may reflect association of a sub-group of patients with a susceptibility to abnormal involuntary movements related to antipsychotic drug exposure.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11317227     DOI: 10.1038/sj.mp.4000842

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  25 in total

Review 1.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

2.  Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms.

Authors:  Cüneyt Güzey; Maria Gabriella Scordo; Edoardo Spina; Veslemøy Malm Landsem; Olav Spigset
Journal:  Eur J Clin Pharmacol       Date:  2007-01-17       Impact factor: 2.953

3.  Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.

Authors:  Jeroen P Koning; Jelle Vehof; Huibert Burger; Bob Wilffert; Asmar Al Hadithy; Behrooz Alizadeh; Peter N van Harten; Harold Snieder
Journal:  Psychopharmacology (Berl)       Date:  2011-07-13       Impact factor: 4.530

Review 4.  Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics.

Authors:  Wolfgang Maier; Astrid Zobel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

Review 5.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

6.  Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages.

Authors:  Richard L Kravitz; Naihua Duan; Joel Braslow
Journal:  Milbank Q       Date:  2004       Impact factor: 4.911

7.  Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients.

Authors:  Chiara Fabbri; Daniel Souery; Raffaella Calati; Concetta Crisafulli; Armando Chierchia; Diego Albani; Gianluigi Forloni; Alberto Chiesa; Rosalba Martines; Othman Sentissi; Julien Mendlewicz; Giovanni De Girolamo; Alessandro Serretti
Journal:  J Neural Transm (Vienna)       Date:  2014-08-17       Impact factor: 3.575

Review 8.  Pharmacogenetics of antipsychotics.

Authors:  Eva J Brandl; James L Kennedy; Daniel J Müller
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

Review 9.  Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation.

Authors:  Bernard Lerer; Ronnen H Segman
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

10.  Genetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesia.

Authors:  Takahiro Shinkai; Osamu Ohmori; Chima Matsumoto; Hiroko Hori; James L Kennedy; Jun Nakamura
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.